Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

NCT06120140 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

305

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Amivantamab IV
DRUG: Amivantamab SC
DRUG: Lazertinib
DRUG: Doxycycline
DRUG: Minocycline
DRUG: Clindamycin
DRUG: Chlorhexidine
OTHER: Noncomedogenic skin moisturizer
OTHER: Ruxolitinib
OTHER: Tacrolimus
DRUG: Zinc gluconate
DRUG: Propranolol
DRUG: Timolol
DRUG: Clobetasol

Sponsor

Janssen Research & Development, LLC